A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)

J Biomol Struct Dyn. 2022 Feb;40(3):1101-1108. doi: 10.1080/07391102.2020.1822209. Epub 2020 Sep 18.

Abstract

The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a worldwide outbreak of coronavirus disease 19 (COVID-19), which rapidly evolved as a global concern. The efforts of the scientific community are pointed towards the identification of promptly available therapeutic options. RNA-dependent RNA polymerase (RdRp) is a promising target for developing small molecules to contrast SARS-CoV-2 replication. Modern computational tools can boost identification and repurposing of known drugs targeting RdRp. We here report the results regarding the screening of a database containing more than 8800 molecules, including approved, experimental, nutraceutical, illicit, withdrawn and investigational compounds. The molecules were docked against the cryo-electron microscopy structure of SARS-CoV-2 RdRp, optimized by means of molecular dynamics (MD) simulations. The adopted three-stage ensemble docking study underline that compounds formerly developed as kinase inhibitors may interact with RdRp.Communicated by Ramaswamy H. Sarma.

Keywords: RdRp; SARS-CoV-2; molecular modelling; remdesivir; repurposing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • COVID-19*
  • Cryoelectron Microscopy
  • Drug Repositioning*
  • Humans
  • Molecular Docking Simulation
  • RNA, Viral
  • RNA-Dependent RNA Polymerase
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • RNA, Viral
  • RNA-Dependent RNA Polymerase

Grants and funding

This work was granted by University of Brescia.